SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM adaptive trial platform evaluating pamrevlumab [and...
FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference
SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating pamrevlumab, a monoclonal antibody to connective tissu… […]
SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: […]
FibroGen Receives One of China Pharmaceutical Industry?s Highest Awards for Clinical Innovation for Roxadustat
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize ????in China for ?On-Market Innovative Drug with Highest Clinical Value.?? The award was received by it… […]